{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T13:09:43Z","timestamp":1776863383794,"version":"3.51.2"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001697","name":"Keio University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001697","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Growth Hormone & IGF Research"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.ghir.2022.101500","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T12:01:40Z","timestamp":1662638500000},"page":"101500","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Pharmacokinetics and pharmacodynamics of once-weekly administration of JR-142, a long-acting albumin-fused human growth hormone: A rondemized, placebo-controlled phase 1 study"],"prefix":"10.1016","volume":"67","author":[{"given":"Yasuko","family":"Owada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuji","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohtaro","family":"Minami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Hirato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Mita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuyoshi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Tanizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ghir.2022.101500_bb0005","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/MED.0b013e32834ec952","article-title":"Diagnosis of growth hormone deficiency in childhood","volume":"19","author":"Stanley","year":"2012","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"issue":"6","key":"10.1016\/j.ghir.2022.101500_bb0010","first-page":"359","article-title":"Seven years of safety and efficacy of the recombinant human growth hormone Omnitrope in the treatment of growth hormone deficient children: results of a phase III study","volume":"72","author":"Romer","year":"2009","journal-title":"Horm. Res."},{"issue":"10","key":"10.1016\/j.ghir.2022.101500_bb0015","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s12325-011-0063-8","article-title":"Long-term safety and efficacy of the recombinant human growth hormone Omnitrope\u00ae in the treatment of Spanish growth hormone deficient children: results of a phase III study","volume":"28","author":"L\u00f3pez-Siguero","year":"2011","journal-title":"Adv. Ther."},{"issue":"2","key":"10.1016\/j.ghir.2022.101500_bb0020","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4158\/EP.14.2.143","article-title":"Compliance and persistence in pediatric and adult patients receiving growth hormone therapy","volume":"14","author":"Rosenfeld","year":"2008","journal-title":"Endocr. Pract."},{"issue":"1","key":"10.1016\/j.ghir.2022.101500_bb0025","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1515\/jpem-2017-0157","article-title":"Adherence to growth hormone therapy in children and its potential barriers","volume":"31","author":"Mohseni","year":"2018","journal-title":"J. Pediatr. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.ghir.2022.101500_bb0030","doi-asserted-by":"crossref","first-page":"e2121","DOI":"10.1210\/clinem\/dgz149","article-title":"Long-acting growth hormone preparations - current status and future considerations","volume":"105","author":"Miller","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.ghir.2022.101500_bb0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016223","article-title":"Non-compliance with growth hormone treatment in children is common and impairs linear growth","volume":"6","author":"Cutfield","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ghir.2022.101500_bb0040","series-title":"PCT Appl. No.: PCT\/JP2016\/076438. PCT Pub. No.: WO2017\/043569. PCT Pub. Date: Mar. 16","article-title":"Human serum albumin mutant","author":"Takahashi","year":"2017"},{"key":"10.1016\/j.ghir.2022.101500_bb0045","doi-asserted-by":"crossref","first-page":"705241","DOI":"10.3389\/fendo.2021.705241","article-title":"Usefulness and potential pitfalls of long-acting growth hormone analogs. Front Endocrinol 2021,12:637209","volume":"12","author":"Yuen","year":"2021","journal-title":"Erratum Front. Endocrinol."},{"issue":"5","key":"10.1016\/j.ghir.2022.101500_bb0050","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1530\/EJE-15-0554","article-title":"Safety, pharmacokinetic and pharmacodynamic properties of TV-1106, a long-acting GH treatment for GH deficiency","volume":"173","author":"Cohen-Barak","year":"2015","journal-title":"Eur. J. Endocrinol."},{"issue":"8","key":"10.1016\/j.ghir.2022.101500_bb0055","doi-asserted-by":"crossref","first-page":"R171","DOI":"10.1530\/EC-17-0203","article-title":"The rationale and design of TransCon growth hormone for the treatment of growth hormone deficiency","volume":"6","author":"Sprog\u00f8e","year":"2017","journal-title":"Endocr. Connect."},{"issue":"4","key":"10.1016\/j.ghir.2022.101500_bb0060","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/cpdd.294","article-title":"Assessment of the pharmacokinetics, pharmacodynamics, and safety of single doses of TV-1106, a long-acting growth hormone, in healthy Japanese and Caucasian subjects","volume":"6","author":"Cohen-Barak","year":"2017","journal-title":"Clin. Pharmacol. Drug Develop."},{"issue":"5","key":"10.1016\/j.ghir.2022.101500_bb0065","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/cpdd.414","article-title":"Pharmacokinetics, pharmacodynamics, and safety of a long-acting human growth hormone (MOD-4023) in healthy Japanese and Caucasian adults","volume":"7","author":"Kramer","year":"2018","journal-title":"Clin. Pharmacol. Drug Develop."},{"issue":"9","key":"10.1016\/j.ghir.2022.101500_bb0070","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1507\/endocrj.EJ12-0110","article-title":"Standardized centile curves and reference intervals of serum insulin-like growth factor-1 (IGF-1) levels in a normal Japanese population using the LMS method","volume":"59","author":"Isojima","year":"2012","journal-title":"Endocr. J."},{"key":"10.1016\/j.ghir.2022.101500_bb0075","first-page":"3527","article-title":"Developments in human growth hormone preparations: sustained-release, prolonged half-life, novel injection devices, and alternative delivery routes","volume":"9","author":"Cai","year":"2014","journal-title":"Int. J. Nanomedicine"},{"issue":"1","key":"10.1016\/j.ghir.2022.101500_bb0085","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1297\/cpe.30.35","article-title":"Newly formulated GROWJECT\u00ae is bioequivalent to the prior GROWJECT\u00ae formulation and causes less injection-associated pain","volume":"30","author":"Owada","year":"2021","journal-title":"Clin. Pediatr. Endocrinol."},{"issue":"10","key":"10.1016\/j.ghir.2022.101500_bb0090","doi-asserted-by":"crossref","first-page":"E1819","DOI":"10.1210\/jc.2014-1702","article-title":"A reversible albumin-binding growth hormone derivative is well tolerated and possesses a potential once-weekly treatment profile","volume":"99","author":"Rasmussen","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2022.101500_bb0095","unstructured":"EU Clinical Trial Register. EudraCT number: 2013-004468-69. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-004468-69\/results (accessed 15th February 2022)."},{"issue":"3","key":"10.1016\/j.ghir.2022.101500_bb0100","doi-asserted-by":"crossref","first-page":"R126","DOI":"10.1530\/EC-18-0047","article-title":"Growth hormone research society perspective on biomarkers of GH action in children and adults","volume":"7","author":"Johannsson","year":"2018","journal-title":"Endocr. Connect."}],"container-title":["Growth Hormone & IGF Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096637422000570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096637422000570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T22:52:40Z","timestamp":1761087160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096637422000570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":19,"alternative-id":["S1096637422000570"],"URL":"https:\/\/doi.org\/10.1016\/j.ghir.2022.101500","relation":{},"ISSN":["1096-6374"],"issn-type":[{"value":"1096-6374","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics and pharmacodynamics of once-weekly administration of JR-142, a long-acting albumin-fused human growth hormone: A rondemized, placebo-controlled phase 1 study","name":"articletitle","label":"Article Title"},{"value":"Growth Hormone & IGF Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ghir.2022.101500","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101500"}}